A New Step Into the Future of Heart Recovery
With the acquisition through Johnson & Johnson MedTech, the brand identity of Abiomed and therefore also Impella heart pumps will be different from January 2025. This means it will visually adapt to the brand identity of Johnson & Johnson MedTech. However, the content that is available to you across our website will remain the same - same content, new design.
DanGer Shock Results from Dr. Jacob Møller at ACC 2024
Jacob Møller, MD, the principal investigator of the DanGer Shock trial, discusses study results he presented at ACC 2024.
Protected PCI
Learn more about Protected PCI.
Surgical Applications
Learn more about the surgical applications for Impella heart pumps.
AMI Cardiogenic Shock
Learn more about Impella heart pumps in the context of cardiogenic shock management.
Right-sided Heart Failure
Learn more about Impella RP and right-sided heart failure.
References
- Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med.
NPS-2641